Trial Profile
A clinical study of JX 594 in patients with metastatic melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2011
Price :
$35
*
At a glance
- Drugs Pexastimogene devacirepvec (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 05 Aug 2011 New trial record
- 02 Aug 2011 Results published in Molecular Therapy.